This bill mandates that new or significantly renovated federal public buildings costing over $50 million (adjusted for inflation) prioritize classical or traditional architectural styles - such as Neoclassical, Georgian, or Greek Revival - over modern styles like Brutalist or Deconstructivist. It requires federal agencies, particularly the General Services Administration (GSA), to seek community input on designs, ensure architects reviewing projects have classical architecture expertise, and justify any deviation from preferred styles with detailed cost and aesthetic analyses. The law applies to courthouses, agency headquarters, and National Capital region buildings, excluding infrastructure projects. Annual reports to Congress will track compliance with these architectural standards.
This bill requires most health insurance plans to cover HIV prevention services - including PrEP and PEP drugs, related lab tests, counseling, and monitoring - without cost-sharing (like copays or deductibles) or prior approval. It applies to private insurance, Medicare, Medicaid/CHIP, and federal employee health plans, directly affecting people who use HIV prevention medications. Key provisions mandate 100% coverage for FDA-approved HIV prevention drugs, eliminate cost-sharing for these services, and prohibit insurers from requiring preauthorization for them. The bill defines covered services to include all necessary components of HIV prevention care as outlined in current public health guidelines.
HR 5126, the HIV Prevention Now Act, appropriates $2.165 billion for the CDC's National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention for fiscal year 2026. This funding is in addition to existing CDC appropriations and must be used exclusively by that specific center for its programs, with no transfer to other entities. The bill directly affects the CDC's public health operations by providing dedicated resources for prevention and treatment programs targeting HIV, viral hepatitis, STDs, and tuberculosis. It does not create new policies or alter eligibility but ensures sustained funding for existing prevention efforts at the federal level.
HR 5156, the COUNT Act, requires federal agencies to share specific immigration and demographic data with the Department of Commerce to improve national citizenship statistics. It mandates agencies like DHS, SSA, and HHS to provide access to records including immigration files, passport applications, and Medicaid data, while directing the Census Bureau to add a citizenship question to the 2030 census and American Community Survey. The bill also directs the Commerce Department to seek state administrative records for citizenship data and requires annual reports to Congress on state cooperation. This directly affects federal and state agencies by altering data-sharing protocols for immigration and citizenship tracking.
S 2697, the National Biotechnology Safety Act, establishes a National Science Foundation program to fund research on the environmental, health, and safety risks of biotechnology products like gene-edited crops or microbes. It authorizes $50 million annually (2026-2030) for research grants to universities, nonprofits, industry, and consortia, focusing on identifying unintended effects, managing risks, and monitoring gene drives. The bill also mandates a two-phase study by the National Academies to compare biotech tools with conventional methods and recommend risk-based regulatory approaches. This research aims to inform federal agencies (like USDA and EPA) and develop clearer safety standards for biotech products, directly affecting researchers, biotech developers, and regulators.
This bill creates a new Assistant Secretary for National Security within the U.S. Department of Agriculture (USDA), to be appointed within 180 days of enactment. The position will serve as the USDA's primary advisor on national security matters related to food and agriculture, coordinate with agencies like Homeland Security and the National Security Council, and oversee efforts to identify vulnerabilities in areas like supply chains, foreign ownership of farmland, and emerging technologies (such as AI and biotechnology). It also requires the USDA to submit biennial reports to Congress detailing gaps in national security efforts, actions taken to address them, and policy recommendations. The bill directly affects USDA operations and interagency coordination, focusing on protecting the U.S. food and agriculture system from security threats.
S 2702 requires K-12 schools receiving federal funds to obtain parental consent before accommodating students' gender identity expressions that differ from their biological sex. It prohibits schools from hiding such information from parents, encouraging students to conceal gender identity concerns, or facilitating referrals for gender transition procedures without consent. Schools must publicly post compliance policies and provide written policies to families, with violations allowing parents to sue for injunctive relief, attorney fees, and compensation for "harm" from gender transition treatments. The bill directly affects school districts, staff, and families of students under 18, mandating parental involvement in decisions about gender identity accommodations.
S 2696 establishes a nonprofit "Foundation for Enabling Biotechnology Innovation" under the National Science Foundation to accelerate the commercialization of biotechnology products in the U.S. The Foundation will foster public-private partnerships, convene stakeholders to develop recommendations on emerging biotech products, and support international market access for U.S. biotech companies. It will operate through a diverse Board of Directors (excluding federal employees) and receive $4 million annually from the NSF, with no regulatory authority. The Foundation aims to complement existing federal efforts without duplicating them, focusing on collaboration, education, and market development for biotechnology products.
The Biobased Market Expansion Act of 2025 amends federal procurement rules to increase government purchases of biobased products. It requires federal agencies to annually raise their biobased product procurement targets, promote domestically produced biobased items, and establish price preferences for these products. Agencies must also provide staff training, update procurement catalogs to clearly identify eligible biobased products, and report compliance details. The bill directly affects federal procurement offices and biobased product manufacturers, with a Comptroller General review mandated within two years to assess implementation and recommend improvements.
The Synthetic Biology Advancement Act of 2025 establishes a National Synthetic Biology Center within the U.S. Department of Agriculture to award competitive grants to eligible land-grant universities (1862, 1890, and 1994 institutions). The center funds research focused on synthetic biology applications in agriculture, including gene editing, microbiomes, AI-driven modeling, and sustainable food production systems. Grants require partnerships with entities like National Laboratories or nonprofits and must address specific priorities like climate-resilient crops or new protein sources. The bill authorizes $5 million annually for grants and $1 million annually for center operations from 2026-2030, with mandatory progress reports to Congress.
The Agricultural Biotechnology Coordination Act (S 2692) creates a new Office of Biotechnology Policy within the U.S. Department of Agriculture to coordinate the Department's work on biotechnology, biomanufacturing, synthetic biology, and related emerging technologies. The Office will develop policies covering research, regulation, labeling, commercialization, and trade, while coordinating with agencies like the Environmental Protection Agency and Food and Drug Administration. It will also consult with biotechnology developers, farmers, and researchers to shape policies affecting these stakeholders. The bill establishes this office to improve interagency coordination without altering existing regulations or creating new requirements.
This bill prohibits Members of Congress, their spouses, and dependent children from owning or trading certain investments, including stocks, commodities, and derivatives (referred to as "covered investments"). It requires affected individuals to divest these investments within 90-180 days, with specific exemptions for Treasury bonds, diversified mutual funds, small business interests, and family trusts meeting strict conditions. Violations incur penalties of 10% of the investment's value plus disgorgement of profits, paid directly to the U.S. Treasury. The law applies to all covered individuals during federal service, with exceptions for investments acquired through inheritance or occupational trading (e.g., a spouse’s finance job).
